Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to Scientific Community Via Opnme.Com to Unlock Their Full Potential
November 21, 2017
November 21, 2017
INGELHEIM, Germany, Nov. 21 -- Boehringer Ingelheim, a pharmaceutical company, issued the following news release:
Boehringer Ingelheim today announced the launch of opnMe.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnMe.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative . . .
Boehringer Ingelheim today announced the launch of opnMe.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnMe.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative . . .